LACTOLOGY FOUNDATION

ATC Class A07EC — Aminosalicylic Acid and Similar Agents

ATC class and general pharmacology

ATC class A07EC ("Aminosalicylic acid and similar agents") groups the intestinal anti-inflammatory aminosalicylates used primarily in the maintenance and induction of remission of inflammatory bowel disease (ulcerative colitis and, for some agents, Crohn's disease). The class comprises four principal molecules: sulfasalazine (A07EC01), mesalazine/mesalamine (A07EC02), olsalazine (A07EC03), and balsalazide (A07EC04) (WHO ATC/DDD Index; Wikipedia ATC A07). Pharmacologically, all members are prodrug or direct-delivery vehicles for 5-aminosalicylic acid (5-ASA), a salicylate derivative that exerts a predominantly topical anti-inflammatory action on the colonic mucosa. The proposed mechanism involves inhibition of cyclooxygenase and 5-lipoxygenase pathways, reduced synthesis of prostaglandins and leukotrienes, scavenging of reactive oxygen species, and modulation of nuclear factor-κB signaling in colonic epithelial and immune cells.atcddd.fhi+2

The class-defining pharmacological distinction lies in the delivery strategy used to protect 5-ASA from absorption in the proximal gastrointestinal tract and to release it at the target site (distal ileum and colon):

• Sulfasalazine is an azo-linked prodrug of 5-ASA and sulfapyridine, cleaved by colonic bacterial azoreductases.
• Olsalazine and balsalazide use analogous azo-bond or carrier strategies to deliver 5-ASA to the colon while limiting systemic absorption.
• Mesalazine (mesalamine) is 5-ASA itself, formulated with pH-dependent, time-dependent, or sustained-release coatings, and is also available in rectal formulations (suppositories, enemas).

As a general class characteristic, oral bioavailability of active 5-ASA in the systemic circulation is low, since the pharmacological strategy is designed to maximize luminal/mucosal concentration while minimizing systemic exposure. Absorbed 5-ASA undergoes rapid hepatic and intestinal N-acetylation to N-acetyl-5-ASA (Ac-5-ASA), a metabolite considered therapeutically inactive against inflammatory bowel disease. Individual agents differ in the fraction delivered as free 5-ASA versus non-5-ASA carrier fragments (e.g., sulfapyridine in sulfasalazine), which is clinically important because much of the toxicological burden of the class is attributable to these carrier moieties rather than to 5-ASA itself. Detailed pharmacokinetic and formulation-specific data for each individual substance will be addressed in dedicated monographs for A07EC01–A07EC04.

Toxicological profile

As a class, aminosalicylates are regarded as having a comparatively favorable systemic safety margin relative to other agents used in inflammatory bowel disease (e.g., thiopurines, biologics, corticosteroids), owing to low systemic 5-ASA absorption. Nonetheless, class-level toxicological signals include:

• Renal toxicity: Interstitial nephritis and, less commonly, nephrotic syndrome or renal impairment have been described across 5-ASA–derived agents, believed to result from direct tubular exposure to circulating salicylate-related metabolites; periodic renal function monitoring is a general recommendation across the class.
• Hematological effects: Agents containing a sulfonamide-related carrier (notably sulfasalazine) carry a distinct risk of hemolysis, agranulocytosis, and folate antagonism, in addition to hypersensitivity-type reactions; non-sulfonamide aminosalicylates (mesalazine, olsalazine, balsalazide) are largely free of this specific hazard but are not entirely exempt from hematological idiosyncratic reactions.
• Hepatic effects: Rare hepatotoxicity, including hypersensitivity hepatitis, has been reported across the class.
• Cardiac toxicity: Rare hypersensitivity-mediated myocarditis and pericarditis have been documented with 5-ASA compounds as a class effect.laegemiddelstyrelsen
• Hypersensitivity/paradoxical exacerbation: A subset of patients experience an idiosyncratic exacerbation of colitis symptoms (fever, worsening diarrhea, rash) attributable to the aminosalicylate itself, sometimes indistinguishable from a disease flare.
• Pulmonary toxicity: Eosinophilic pneumonitis and other hypersensitivity pulmonary reactions have been reported, albeit rarely, across the class.

Reproductive and developmental toxicology data across the class are generally reassuring: aminosalicylates cross the placenta but animal and available human pregnancy data have not demonstrated a consistent teratogenic signal, and there is no established adverse effect on male or female fertility from 5-ASA itself, though sulfasalazine is specifically associated with reversible impairment of sperm quality. Substance-specific toxicological detail, dose-dependence, and comparative risk quantification will be developed in the individual monographs for each active substance.

Lactation pharmacology and infant exposure

Across the class, the shared pharmacological property most relevant to lactation is the low systemic bioavailability of the parent aminosalicylate compounds, which correspondingly limits their transfer into breast milk. Published data (predominantly for mesalazine and sulfasalazine, used as class-representative reference points) indicate:

• Concentrations of free 5-ASA in breast milk are consistently low, generally producing a relative infant dose well below the conventional 10% safety threshold (Gut/PMC; E-lactation Mesalazine).pmc.ncbi.nlm.nih+1
• The inactive metabolite N-acetyl-5-ASA is excreted into milk at substantially higher concentrations than the parent compound (in some analyses roughly 1,000-fold higher), but its pharmacological inertness with respect to the class's anti-inflammatory action limits its clinical significance for the infant, although its own infant-exposure toxicology has not been formally studied.pmc.ncbi.nlm.nih
• For sulfonamide-carrier agents (sulfasalazine), the carrier fragment sulfapyridine is detectable in both milk and infant serum, introducing a class-distinct additional exposure route not shared by non-sulfonamide members (mesalazine, olsalazine, balsalazide) (StatPearls; Drugs.com).ncbi.nlm.nih+1
• Route of administration (oral versus rectal) and dose influence the magnitude of systemic/milk exposure, with rectal formulations generally associated with lower systemic absorption.

Reported infant clinical findings associated with maternal aminosalicylate use during lactation, while uncommon, recur as a class-level pattern across published case series: mild watery or, less frequently, bloody diarrhea, thought in most instances to represent a hypersensitivity-type reaction to the aminosalicylate moiety rather than direct pharmacological toxicity (MotherToBaby; NHS Mesalazine). For sulfonamide-containing agents specifically, a theoretical and case-documented risk of neonatal hemolysis exists, particularly relevant to full-term infants within the first 8 days of life and to infants with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Substance-specific quantitative milk/plasma ratios, relative infant dose calculations, and infant pharmacokinetic data will be detailed in the individual active-substance monographs.ncbi.nlm.nih+2

Lactological safety assessment and clinical recommendations

At the class level, aminosalicylates (A07EC) are generally considered compatible with breastfeeding by major expert bodies and consensus guidelines, reflecting consistently low systemic and milk transfer of the pharmacologically active 5-ASA moiety (American Journal of Gastroenterology/academic.oup.com; E-lactation Sulfasalazine). The following class-level clinical principles apply, pending substance-specific refinement in subsequent monographs:academic.oup+1

1. Continuation of breastfeeding is not generally contraindicated for mothers requiring maintenance aminosalicylate therapy for inflammatory bowel disease, as disease control benefits typically outweigh the low absolute infant exposure risk.
2. Non-sulfonamide aminosalicylates (mesalazine, olsalazine, balsalazide) are preferentially favored over sulfasalazine when initiating or switching therapy in a lactating patient, owing to the absence of the sulfapyridine-related hemolysis risk.
3. Breastfed infants of mothers using any class member should be monitored clinically for diarrhea (watery or bloody) and, for sulfonamide-containing agents, for signs of hemolysis (pallor, jaundice, lethargy), with particular vigilance in the neonatal period and in infants with known or suspected G6PD deficiency.
4. Rectal formulations, where clinically equivalent, may be considered to minimize systemic/milk exposure relative to oral high-dose regimens, although this is not an absolute requirement given the overall favorable class profile.
5. Routine infant blood monitoring is not considered mandatory for asymptomatic infants but should be pursued if clinical symptoms (diarrhea, jaundice, poor feeding) emerge.
6. As with all agents in this class, individualized risk-benefit assessment should account for maternal disease activity, dose, formulation, infant gestational/postnatal age, and any predisposing infant conditions (e.g., G6PD deficiency, prematurity).

This class-level assessment provides the general regulatory and pharmacological framework for A07EC; comprehensive, substance-specific lactational risk categorization, dosing considerations, and case-level evidence for sulfasalazine, mesalazine, olsalazine, and balsalazide will be presented in their respective individual monographs.